Array BioPharma Articles

Oncothyreon and Array collaborate on anti-HER2 compound ARRY-380

30 May 2013

Selumetinib is first drug to help patients with recurrent low-grade ovarian cancer

11 February 2013

First success of selumetinib, a targeted therapy in most common NSCLC

29 November 2012

Array BioPharma presents encouraging Ph II selumetinib results in ovarian cancer

5 April 2012

Array BioPharma set to earn up to $467 million from oncology deal with Novartis

20 April 2010

Showing 1-5 of 5 articles

Go to beginningPrevious
  • 1
NextGo to end